What is Third Harmonic Bio?
Third Harmonic Bio is a clinical-stage biopharmaceutical company focused on pioneering an innovative oral treatment for severe allergic and inflammatory conditions. Headquartered in Cambridge, Massachusetts, the company is advancing its pipeline with the aim of addressing significant unmet needs in immunology.
How much funding has Third Harmonic Bio raised?
Third Harmonic Bio has raised a total of $105M across 1 funding round:
Series B
$105M
Series B (2022): $105M with participation from BVF Partners and General Atlantic
Key Investors in Third Harmonic Bio
BVF Partners
BVF Partners is a private investment partnership that specializes in public biotechnology investments, focusing on small-cap companies with rigorous diligence and long-term partnership.
General Atlantic
General Atlantic is a global growth equity firm providing capital and strategic support to high-growth companies across various sectors, including life sciences, with a focus on accelerating growth and international expansion.
What's next for Third Harmonic Bio?
The substantial enterprise-level funding, including the recent Series B financing, positions Third Harmonic Bio for accelerated development and potential commercialization of its therapeutic candidates. This strategic backing from prominent investors suggests confidence in the company's technology and its potential to capture a significant share of the allergy and inflammation market. Future growth will likely involve advancing clinical trials and expanding its research and development capabilities.
See full Third Harmonic Bio company page
